Press Releases

Press Releases

Press Releases

Date Title and Summary Additional Formats
Dec 09, 2005
Genomic Health Announces Study Results Demonstrating Oncotype DX™ Changed Adjuvant Treatment Approach for 25 Percent of Early-Stage Breast Cancer Patients
SAN ANTONIO, Dec 09, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of a community-based, investigator-sponsored study that demonstrated its Oncotype DX(TM) 21-gene panel breast cancer test, which quantifies the likelihood of
Dec 05, 2005
Genomic Health Announces Oncotype DX™ Study Results to Be Presented at 28th Annual San Antonio Breast Cancer Symposium
REDWOOD CITY, Calif., Dec 05, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Genomic Health, Inc. (Nasdaq: GHDX) announced today that results from three new analyses of the company's Oncotype DX(TM) breast cancer test, which quantifies the likelihood of recurrence and predicts chemotherapy
Nov 03, 2005
Genomic Health, Inc. Announces Third Quarter 2005 Financial Results
- First Conference Call as Public Company Today at 4:30 p.m. ET -
- Reports Product Adoption and Reimbursement Progress -
- New Partnership with Bristol-Myers Squibb/ImClone Systems -
Oct 28, 2005
Genomic Health Announces Third Quarter 2005 Financial Results Conference Call Thursday, November 3, 2005
Genomic Health Announces Third Quarter 2005 Financial Results Conference Call Thursday, November 3, 2005 REDWOOD CITY, Calif., Oct 28, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast
Sep 28, 2005
Genomic Health Announces Initial Public Offering
Genomic Health Announces Initial Public Offering REDWOOD CITY, Calif., Sept. 28, 2005 /PRNewswire-FirstCall/ -- Genomic Health, Inc. today announced the pricing of its initial public offering of 5,016,722 shares of its Common Stock at $12.00 per share. J.P. Morgan Securities Inc.
May 17, 2005
Multiple Studies Presented at the American Society of Clinical Oncology Meeting Show Consistent Positive Results for the Oncotype DX™ Breast Cancer Assay
-- Data Presentations Reinforce Recurrence Score's Ability to Predict Chemotherapy Benefit; Capture Prognosis and Response to Tamoxifen

-- ASCO selects National Surgical Adjuvant Breast and Bowel Project (NSABP) and Genomic Health chemotherapy response study for "Best of Oncology" special session
May 13, 2005
Genomic Health, Inc. Announces Publication of Comprehensive Economic Analysis Confirming Cost-Effectiveness of Oncotype DX™ in the American Journal of Managed Care
Findings Reinforce Value of Recurrence Score Testing and Provide Support for Favorable Reimbursement Coverage Policies
Dec 10, 2004
NIH/NCI Press Release: Molecular Test Can Predict Both the Risk of Breast Cancer Recurrence and Who Will Benefit From Chemotherapy
NIH/NCI Press Release: Molecular Test Can Predict Both the Risk of Breast Cancer Recurrence and Who Will Benefit From Chemotherapy A new test can predict both the risk of breast cancer recurrence and may identify women who will benefit most from chemotherapy, according to research supported by the
Dec 10, 2004
NSABP and Genomic Health Announce Positive Study Results Demonstrating Oncotype DX Genomic Breast Cancer Assay Predicts Chemotherapy Response
Dec 09, 2004
Kaiser Permanente Press Release: Kaiser Permanente Research: Study of Early Stage Breast Cancer Patients Identifies Women at Low Risk of Breast Cancer Mortality
21-gene test predicts mortality risk in epidemiological study